Jazz Pharmaceuticals plc Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Jazz Pharmaceuticals plc (JAZZ) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $47.88 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-24
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $47.88M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $47.49M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $48.40M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $42.80M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $47.88M 10-K · filed 2026-02-24 |
| 2024-12-31 | $47.49M 10-K · filed 2026-02-24 |
| 2023-12-31 | $48.40M 10-K · filed 2025-02-26 |
| 2022-12-31 | $42.80M 10-K · filed 2024-02-28 |
| 2021-12-31 | $37.29M 10-K · filed 2023-03-01 |
| 2020-12-31 | $26.09M 10-K · filed 2022-03-01 |
| 2019-12-31 | $26.09M 10-K · filed 2021-02-23 |
| 2018-12-31 | $24.59M 10-K · filed 2020-02-25 |
| 2017-12-31 | $23.13M 10-K · filed 2019-02-26 |
| 2016-12-31 | $27.52M 10-K · filed 2018-02-27 |
| 2015-12-31 | $20.05M 10-K · filed 2017-02-28 |
| 2014-12-31 | $14.03M 10-K · filed 2016-02-23 |
| 2013-12-31 | $8.12M 10-K · filed 2015-02-24 |
| 2012-12-31 | $3.88M 10-K · filed 2014-02-25 |
| 2011-12-31 | $6.29M 10-K · filed 2013-02-26 |
| 2010-12-31 | $2.59M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |